Patients with non-small-cell lung cancer (NSCLC) who express high levels of transcriptional coactivator with PDZ-binding motif (TAZ) may be a clinically distinct subgroup with an unfavourable prognosis, researchers report. To investigate further, Saito and team initially measured TAZ expression in tumour samples from 196 patients in the well-characterised Uppsala lung cancer cohort.

READ FULL ARTICLE Curated publisher From News Medical